secwatch.observer — SEC 8-K summary
======================================

Issuer:     MADRIGAL PHARMACEUTICALS, INC. (MDGL)
CIK:        0001157601
Form:       8-K
Filed at:   2024-02-28T23:59:59+00:00
Accession:  0001193125-24-049136
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Madrigal names Mardi Dier as CFO; Alex Howarth transitions to advisor; GC Brian Lynch to depart by May 31
--------------------------------------------------------------------------------

- Mardi Dier appointed SVP & CFO effective March 11, 2024; previously CFO of Acelyrin (IPO), Ultragenyx, Portola.
- Dier receives $550K base salary, 45% target bonus, and $6.7M equity grant (RSUs, options, PSUs) under 2023 Inducement Plan.
- Outgoing CFO Alex Howarth remains Senior Advisor to May 31; separation includes 12-month salary, target bonus, equity acceleration, health benefits.
- SVP & General Counsel Brian Lynch to depart by May 31; similar separation terms: 12-month salary, target bonus, equity acceleration, health benefits.
- No disagreements with accounting policies or internal controls related to either departure.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1157601/000119312524049136/0001193125-24-049136-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1157601/000119312524049136/d757603d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-049136

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer